Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...

Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical interventions including new drugs, devices, vaccines and lifestyle modifications ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...

Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...